G protein pathway suppressor 2 (GPS2) acts as a tumor suppressor in liposarcoma

Liposarcoma(LPS) is the most common type of soft tissue sarcoma accounting for 20 % of all adult sarcomas. However, the molecular pathogenesis of this malignancy is still poorly understood. Here, we showed that GPS2 expression was downregulated in LPS and correlated with the prognosis of this diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xiao-Dong, Xiao, Feng-Jun, Wang, Shao-Xia, Yin, Rong-Hua, Lu, Can-Rong, Li, Qing-Fang, Liu, Na, zhang, Ying, Wang, Li-Sheng, Li, Pei-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097092/
https://www.ncbi.nlm.nih.gov/pubmed/27460081
http://dx.doi.org/10.1007/s13277-016-5220-x
Descripción
Sumario:Liposarcoma(LPS) is the most common type of soft tissue sarcoma accounting for 20 % of all adult sarcomas. However, the molecular pathogenesis of this malignancy is still poorly understood. Here, we showed that GPS2 expression was downregulated in LPS and correlated with the prognosis of this disease. In vitro study showed that knockdown of GPS2 resulted in enhanced proliferation and migration of LPS cell line SW872, without significant influence of cell death. Conclusively, our results suggest that GPS2 may act as a tumor suppressor in LPS and serve as a potential prognosis marker for this disease.

Ejemplares similares